Seagen's Tukysa label expanded; ADARx gets $46M script for RNA trial
Seagen just scored another approval for one of its lead drugs.
Tukysa won accelerated approval from the FDA on Thursday to be used in combination …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
